| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5965584 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6166042 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6172090 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6166043 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US7919116 | TAKEDA PHARMS USA | Controlled release metformin formulations |
Mar, 2018
(6 years ago) | |
| US8475841 | TAKEDA PHARMS USA | Controlled release metformin formulations |
Mar, 2018
(6 years ago) | |
| US6495162 | TAKEDA PHARMS USA | Controlled release oral tablet having a unitary core |
Mar, 2018
(6 years ago) | |
| US6099859 | TAKEDA PHARMS USA | Controlled release oral tablet having a unitary core |
Mar, 2018
(6 years ago) | |
| US6866866 | TAKEDA PHARMS USA | Controlled release metformin compositions |
Mar, 2021
(3 years ago) | |
| US6790459 | TAKEDA PHARMS USA | Methods for treating diabetes via administration of controlled release metformin |
Mar, 2021
(3 years ago) | |
| US8470368 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Sep, 2023
(7 months ago) | |
| US8668931 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Sep, 2023
(7 months ago) | |
| US9060941 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Sep, 2023
(7 months ago) | |
| US7959946 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Jul, 2026
(2 years from now) | |
| US7785627 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Jul, 2026
(2 years from now) | |
Actoplus Met Xr is owned by Takeda Pharms Usa.
Actoplus Met Xr contains Metformin Hydrochloride; Pioglitazone Hydrochloride.
Actoplus Met Xr has a total of 15 drug patents out of which 13 drug patents have expired.
Expired drug patents of Actoplus Met Xr are:
- US5965584
- US6166042
- US6172090
- US6166043
- US7919116
- US8475841
- US6495162
- US6099859
- US6866866
- US6790459
- US8470368
- US8668931
- US9060941
Actoplus Met Xr was authorised for market use on 12 May, 2009.
Actoplus Met Xr is available in tablet, extended release;oral dosage forms.
Actoplus Met Xr can be used as adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are already treated with a pioglitazone and metformin, adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with pioglitazone and metformin or who have inadequate glycemic control on pioglitazone or metformin alone, to reduce gastrointestinal side effects administer with a meal; as starting dose administer once daily with evening meal.
The generics of Actoplus Met Xr are possible to be released after 31 July, 2026.
Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 12 May, 2009
Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with pioglitazone and metformin or who have inadequate glycemic control on piog...
Dosage: TABLET, EXTENDED RELEASE;ORAL
ACTOPLUS MET XR family patents
